Families' Experiences of Paediatric ICC Diagnosis

NCT ID: NCT02737111

Last Updated: 2016-05-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2016-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to further understand the experiences of children, their parents and siblings around the time when the child and their family are informed of a diagnosis of an inherited cardiac condition (ICC). The researchers are interested to understand how families experience the process of receiving a diagnosis of an ICC, and explore experiences from multiple perspectives within the family (i.e. parents, children and siblings).

The Primary Project Objective:

How do children, their parents and siblings experience the communication of a diagnosis of an inherited cardiac condition (ICC)? What is found to be helpful and less helpful?

The Secondary Project Objective:

To explore qualitatively how families experience the communication of a positive diagnosis for an inherited cardiac condition for a child and will seek the perspectives of the child with the diagnosis, their siblings and parents.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background Information and Study Rationale:

An ICC comprise of a number of conditions that affect either the heart muscle (cardiomyopathies), or the electrical circuits of the heart (ion channelopathies). ICCs can result in the heart working ineffectively, dangerous arrhythmias and sudden death. The last decade has seen dramatic advances in understanding of the pathology of ICCs. More than 50 ICCs have been recognised and genetics tests are increasingly available. Epidemiological evidence suggests a combined total prevalence for ICCs of about 340,000 in the UK.

In response to advances in medical and genetic understanding of ICCs, ICC services have also grown dramatically, accompanied by commissiioning guidelines, and when an ICC is diagnosed there are implications not only for the patient themselves but for relatives. For families affected by inherited cardiac conditions, the layers of impact can be complex. When a child receives a positive diagnosis there can be implications for parents and siblings not only of living with the child's diagnosis, but also for one's own health and wellbeing. This can lead to uncertainty about the health of others in the family and subsequent medical investigates.

To the researchers' knowledge, there is little published evidence which aims to understand the experiences of children and their siblings of the communication around their ICC condition. Therefore ICC services risk of relying on our own clinical intuition or the views of parents rather than hearing directly from children and young people themselves. This present study therefore proposed to explore qualitatively how families experience the communication of a positive diagnosis for an inherited cardiac condition for a child and will seek the perspectives of the child with the diagnosis, their siblings and parents.

Participants will be recruited from a ICC service at an NHS Hospital in London. Paedaitric patients (who have been given an ICC diagnosis) and their siblings will be aged 8-16, and their Parents. Patient recruitment at a site will only commence once the trial team has ensured that the following approval/essential documents are in place:

1. The main REC approval,
2. Final sponsorship and/or R\&D approval (NHS Permission),
3. Local Site Delegation of Duties and Signature Log is completed.

All subjects who wish to enter the study will be fully screened and consented by the Chief Investigator (CI), or one of the qualified clinicians involved in the study as the Researchers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inherited Cardiac Conditions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Initial Screening Process

The doctor who meets with the family to share the diagnosis will give the participants a flyer about the research study at the end of their consultation and will briefly explain the study aim and purpose. Following this, the ICC Service Clinical Nurse Specialists (CNS) and the primary researcher will identify patients who meet the inclusion and exclusion criteria and all patients who are eligible to take part will be contact by a CNS shortly after a child receives a diagnosis to follow up with the family, and ask permission for the primary researcher to contact the child's parents to discuss the study.

Intervention Type BEHAVIORAL

Information and Informed Consent

The researcher will contact parents of patients who agreed some weeks after receiving the diagnosis, check inclusion criteria, and information sheets will be provided. Individuals who consent to participate will arrange to meet with the researcher in their family home or at the hospital. When they meet, the researcher will go through the participant information sheet with the individuals, and gain written consent for participation

Intervention Type BEHAVIORAL

Interview

Families who wish to take part will be invited to participate in an interview 2-3 months after they received the diagnosis from the hospital. At least ten families (and therefore at least 30 individuals including children with the diagnosis, parents and siblings) will be interviewed separately, about their experiences of the communication about the diagnosis to them, their child or their siblings. Younger children may do some drawings with the researcher about their experiences, and the researcher will ask questions about these drawings.Participants can be included even if not all family members wish to take part.

Intervention Type BEHAVIORAL

Validated Questionnaires

Each member of the family will complete the mood and quality of life questionnaires.

Intervention Type BEHAVIORAL

Debrief

At the end of each interview the research will explore with the individual to discuss how they found the experience and answer any questions they might have and review the questionnaires that they completed. The researcher will then meet with children and parents together to discuss the experience as a family.Information will be shared with families about options for accessing support including the paediatric psychology service at the hospital or local support services, if they wish. After the interviews, the researcher will send a letter to participants GP and medical team to inform them that they are taking part.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Children aged 8 - 16 who have received a positive diagnosis of an inherited cardiac condition from the ICC service at the hospital within the last 3 months, their parents and siblings.
2. Siblings of children who have received a diagnosis of an inherited cardiac condition who are between the ages of 8 and 16 years.
3. Children will only participate if they are already aware of their diagnosis or their sibling's diagnosis.
4. Children will only participate if they and a parent/person with parental responsibility have both consented to take part.
5. Parents will only take part if they have given informed consent

Exclusion Criteria

1\. Children who are unable to communicate verbally will not be included in the research as they would be unable to consent to their involvement in the research and alternative means of data collection would be required.

Discontinuation/ withdrawal of Pariticpants and Stopping Rules:

Participants can withdraw their participation from the study at any time without giving a reason and if this happens, the data collected from their interviews/questionnaires will not be used in the study results. Adult participants will be told that they can tell the researcher if they would like to withdraw. The researcher will agree a word or sign with child participants to indicate that they would like to stop taking part and the researcher will then ask them whether they would like the data used to be included in the results of the study.

The researcher will continue to recruit participants until there is sufficient data for qualitative analysis of interviews.

It is unlikely that the study will be stopped prematurely but this might occur if insufficient numbers of participants are able to be recruited from one or more of the patient samples (i.e. children with a diagnosis, parents or siblings) in the designated time frame.
Minimum Eligible Age

8 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ben Williams Trust

OTHER

Sponsor Role collaborator

Royal Brompton & Harefield NHS Foundation Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jan Till, Doctor

Role: PRINCIPAL_INVESTIGATOR

Royal Brompton & Harefield NHS Foundation Trust

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chantell Douglas, Doctor

Role: CONTACT

Michele Puckey

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2015PC002B

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PRecIsion Medicine in CardiomyopathY
NCT04036799 ACTIVE_NOT_RECRUITING
Mild Valvar Pulmonary Stenosis
NCT00277927 TERMINATED